The University of Nebraska Medical Center is involved in an
international registry that’s evaluating new treatments for hepatitis C,
a disease that threatens many baby boomers.
a regional referral center for hepatitis C, is part of the Hepatitis C
Therapeutic Registry and Research Network, or HCV-TARGET. The network
will track thousands of patients over the next five years to monitor the
effectiveness and safety of new drugs to determine which ones are most
effective and can cure the disease most quickly with the fewest side
The network is made up of university and
community physicians at 103 sites in 31 states, Puerto Rico, Canada and
Europe, in partnership with the U.S. Food and Drug Administration.
Anyone being treated for the virus using newer medications is eligible to participate in the registry.